William Pao

Pulmonary and Respiratory Medicine · 2004–2014

A researcher in the Science corpus: 27 papers; trusts 10 researchers and is trusted by 14 researchers here, as inferred from the citation graph.

Subfields

Whom William Pao trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Vincent A. Miller
  2. I. Weinstein
  3. L. Tanoue
  4. J. Mendelsohn
  5. M. Kris
  6. Gregory Riely
  7. J. Engelman
  8. C. Sawyers
  9. D. Bell
  10. C. Yun

Who trusts William Pao overall

  1. B. Chan
  2. Carlos L. Arteaga
  3. J. Engelman
  4. Vincent A. Miller
  5. Gregory Riely
  6. Adi F. Gazdar
  7. C. Sawyers
  8. J. Baselga
  9. H. Shigematsu
  10. J. Markman

Papers from William Pao's perspective

Ordered by how strongly the researchers William Pao trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
  2. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. (Proceedings of the National Academy of Sciences of the United States of America)
  3. Targeted cancer therapy (Nature)
  4. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (Science)
  5. Mutations of the BRAF gene in human cancer (Nature)
  6. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
  7. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. (Cancer Research)
  8. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors (Clinical Cancer Research)
  9. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* (Journal of Biological Chemistry)
  10. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib (Clinical Cancer Research)

Their papers